HRP20010180A2 - N-substituted azabicycloheptane derivatives, production and use thereof - Google Patents
N-substituted azabicycloheptane derivatives, production and use thereof Download PDFInfo
- Publication number
- HRP20010180A2 HRP20010180A2 HR20010180A HRP20010180A HRP20010180A2 HR P20010180 A2 HRP20010180 A2 HR P20010180A2 HR 20010180 A HR20010180 A HR 20010180A HR P20010180 A HRP20010180 A HR P20010180A HR P20010180 A2 HRP20010180 A2 HR P20010180A2
- Authority
- HR
- Croatia
- Prior art keywords
- dihydro
- dioxide
- azabicyclo
- exo
- acid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 3
- UUAVYXKRUSVCDJ-UHFFFAOYSA-N 1-cycloheptylazepane Chemical class C1CCCCCC1N1CCCCCC1 UUAVYXKRUSVCDJ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 10
- 239000000460 chlorine Chemical group 0.000 claims description 7
- 229910052801 chlorine Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical class C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- -1 N-substituted 3-aza-bicyclo[3.2.0]heptane Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- GVYVHZKTSVDMNT-UHFFFAOYSA-N 2,3-dihydro-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NCC2=C1 GVYVHZKTSVDMNT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WJWHNTAKUNTHFX-UHFFFAOYSA-N 1-azabicyclo[3.2.0]heptane Chemical compound C1CCC2CCN21 WJWHNTAKUNTHFX-UHFFFAOYSA-N 0.000 description 1
- UQAWXKDXVXSCRD-UHFFFAOYSA-N 2-(2-chloroethyl)-3,3-diethyl-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2C(CC)(CC)N(CCCl)S(=O)(=O)C2=C1 UQAWXKDXVXSCRD-UHFFFAOYSA-N 0.000 description 1
- PXHFOKDZXZTWOB-UHFFFAOYSA-N 2-(2-chloroethyl)-3,3-dimethyl-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2C(C)(C)N(CCCl)S(=O)(=O)C2=C1 PXHFOKDZXZTWOB-UHFFFAOYSA-N 0.000 description 1
- RSRBLCSRGDWLCA-UHFFFAOYSA-N 3,3-diethyl-2h-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2C(CC)(CC)NS(=O)(=O)C2=C1 RSRBLCSRGDWLCA-UHFFFAOYSA-N 0.000 description 1
- XHTPPQBDONGRAF-UHFFFAOYSA-N 3,3-dimethyl-2h-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2C(C)(C)NS(=O)(=O)C2=C1 XHTPPQBDONGRAF-UHFFFAOYSA-N 0.000 description 1
- VSZZJVQCTKPDCV-UHFFFAOYSA-N 3,3-dimethyl-6-nitro-2h-1,2-benzothiazole 1,1-dioxide Chemical compound [O-][N+](=O)C1=CC=C2C(C)(C)NS(=O)(=O)C2=C1 VSZZJVQCTKPDCV-UHFFFAOYSA-N 0.000 description 1
- PHGXYLFVGTWXKR-UHFFFAOYSA-N 4-chloro-2-(2-chloroethyl)-3,3-dimethyl-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC(Cl)=C2C(C)(C)N(CCCl)S(=O)(=O)C2=C1 PHGXYLFVGTWXKR-UHFFFAOYSA-N 0.000 description 1
- KARYKQNFDNURNN-UHFFFAOYSA-N 4-chloro-3,3-dimethyl-2h-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC(Cl)=C2C(C)(C)NS(=O)(=O)C2=C1 KARYKQNFDNURNN-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Description
Izum se odnosi na nove N-supstituirane derivate azabicikloheptana, na njihovu proizvodnju i na njihovu upotrebu za suzbijanje bolesti.
Derivati ekso-6-fenil-3-azabiciklo[3.2.0]heptana imaju zanimljiva svojstva kao potencijalni neuroleptici (WO 94/00458, WO 95/15312). Ovdje posebno važnu ulogu imaju opaženi visoki afiniteti za D4- i 5-НТ2-receptore.
Najzanimljivija tvar iz gornjeg razreda spojeva s visokim afinitetom za D4/5-HT2A i dobrom selektivnošću prema D2 je (+)-(1S,5R,6S)-ekso-3-[2-[6-(4-fluorfenil)-3-aza-biciklo[3.2.0]heptan-3-il]-etil]-1H,3H-kinazolin-2,4-dion (= tvar A), koji je potencijalni neuroleptik. Međutim, za tvar A postoji gornja granica doziranja zbog produljenja koje se pojavljuje u QT intervalima na srčanom EKG-u.
Mi smo sada pronašli tvari s boljim svojstvima.
Izum se odnosi na N-supstituirane derivate 3-aza-biciklo[3.2.0]heptana formule I
[image]
u kojoj
R1 je fluor ili klor,
R2 i R3 predstavljaju vodik ili C1-C3-alkil, i
R4 je klor, metil, nitro ili amino,
i njihove soli s fiziološki podnošljivim kiselinama.
Prednosni spojevi su oni u kojima
R1 je klor, ponajprije u para položaju,
R2 je vodik ili metil,
R3 je vodik ili metil i
R4 je vodik.
Kao posebno povoljne treba spomenuti slijedeće spojeve:
(+)-(1S,5R,6S)-ekso-2-[2-[6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptan-3-il]-etil]-3,3-dimetil-2,3-dihidro-1,2-benzizotiazol-1,3-dioksid,
(+)-(1S,5R,6S)-ekso-2-[2-[6-(4-klorofenil)-3-azabiciklo-[3.2.0]heptan-3-il]-etil]-2,3-dihidro-1,2-benzizotiazol-1,1-dioksid, i
(+)-(1S,5R,6S)-ekso-2-[2-[6-(4-fluorofenil)-3-azabiciklo[3.2.0]heptan-3-il]-etil]-2,3-dihidro-1,2-benzizotiazol-1,1-dioksid.
Spojevi formule I prema izumu mogu se proizvesti reakcijom spoja formule II
[image]
u kojoj R2, R3 i R4 imaju gore navedena značenja, i Nu je nukleofilna otpusna skupina, s derivatom 3-azabiciklo-[3.2.0]heptana formule III kao (+)-(1S,5R,ekso-6S) enantiomerom
[image]
u kojoj formuli R1 ima gore navedeno značenje, i prema potrebi, pretvorbom tako dobivenog spoja u kiselinsku adicijsku sol s fiziološki podnošljivom kiselinom.
Kao nukleofilne otpusne skupine za Nu u obzir dolaze ponajprije halogeni atomi, posebno brom ili klor.
Reakcija se svrhovito odvija u prisutnosti inertne baze kao što je trietilamin ili kalijev karbonat, kao sredstva za vezanje kiseline, u inertnom otapalu kao što je ciklički zasićeni eter, posebno tetrahidrofuran ili dioksan, ili benzolni ugljikovodik, kao toluen ili ksilen.
Reakcija se općenito odvija pri temperaturi od 20 do 150°C, posebno od 80 do 140°C, i općenito je gotova za 1 do 10 sati.
Spojevi formule I prema izumu mogu se očistiti prekristalizacijom iz uobičajenih organskih otapala, ponajprije iz nižih alkohola kao što je etanol, ili kromatografijoma na stupcu.
Slobodni derivati 3-azabiciklo[3.2.0]heptana formule I mogu se prevesti na uobičajen način u kiselinske adicijske soli s farmakološki prikladnom kiselinom, ponajprije miješanjem otopine s jednim ekivalentom odgovarajuće kiseline. Primjeri farmaceutski prikladnih kiselina jesu solna kiselina, fosforna kiselina, sumporna kiselina, metansulfonska kiselina, sulfaminska kiselina, maleinska kiselina, fumarna kiselina, oksalna kiselina, vinska kiselina ili limunska kiselina.
Spojevi prema izumu imaju dragocjena farmakološka svojstva. Oni se mogu upotrijebiti kao neuroleptici (naročito atipični), antidepresanti, sedativi, hipnotici, zaštitna sredstva za središnji živčani sistem ili sredstva za liječenje ovisnosti o kokainu. Kod spoja prema izumu može se kombinirano pojaviti više od spomenutih načina djelovanja.
Ove tvari su posebno karakterizirane s visokim i selektivnim afinitetom za dopamin D4- i serotonin 2A-receptore.
Produljenja QT intervala, izmjerena primjenom modela na papilarnom mišiću zamoraca, su zanemarivo mala. To znači da su nove tvari dobro podnošljive pri visokim doziranjima.
S tim u skladu izum se također odnosi na terapeutsko sredstvo, koje kao aktivan sastojak sadrži spoj formule I ili njegovu farmakološki prikladnu kiselinsku adicijsku sol zajedno s uobičajenim nosačima i sredstvima za rezređivanje, te na upotrebu novih spojeva za suzbijanje bolesti.
Spojevi prema izumu mogu se dati na uobičajen način oralno ili parenteralno, intravenski ili intramuskularno.
Doziranje ovisi o starosti, stanju i težini pacijenta i o načinu davanja. U pravilu, dnevna doza aktivnog sastojka je obično između pribl. 1 i 100 mg/kg tjelesne težine kod oralnog davanja i između 0,1 i 10 mg/kg tjelesne težine kod parenteralnog davanja.
Novi spojevi mogu se upotrijebiti u konvencionalnim krutim ili tekućim farmaceutskim oblicima, npr. kao neprevučene ili s filmom prevučene tablete, kapsule, prahovi, granule, čepići, otopine, pomasti, kreme ili sprejevi. Oni se proizvode na uobičajen način. U tu svrhu aktivni sastojci se prerade s uobičajenim farmaceutskim pomoćnim sredstvima kao što su veziva za tablete, punila, konzervansi, sredstva za dezintegraciju tableta, regulatori tecivosti, plastifikatori, sredstva za kvašenje, sredstva za dispergiranje, emulgatori, otapala, sredstva za usporavanje oslobađanja, antioksidanti i/ili potisni plinovi (vidi H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). Oblici za aplikaciju dobiveni na taj način normalno sadrže aktivan sastojak količinom od 1 do 99 mas. %.
Tvari formula II i III, potrebne kao polazni materijali za sintezu spojeva prema izumu, su poznate (WO 94/00458; Heterocycles 40 (1), 319-330 (1995); J. Heterocycklic Chem. 18., 85-89 (1981)) ili se mogu sintetizirati iz analognih polaznih materijala primjenom metoda pripravljanja koje su opisane u literaturi.
Za objašnjenje izuma služe slijedeći primjeri:
A Proizvodnja polaznih materijala
a) 2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid
25,3 g (138 mM) saharina doda se u obrocima tijekom 90 min k 7,1 g (187 mM) litij aluminijevog hidrida u 400 ml apsolutnog tetrahidrofurana uz snažno miješanje u atmosferi dušika. Tijekom toga temperaturu se održava pri sobnoj temperaturi hlađenjem na ledu. Nakon miješanja preko noći smjesu se ohladi na ledenoj kupelji i uz snažno miješanje oprezno, kap po kap, doda se vodu i zatim 10%-tnu sumpornu kiselinu. Istaloženi hidroksidi se odsisaju, isperu s THF-om, filtrat se koncentrira, ostatak se podijeli između metilen klorida i vode, zatim se zakiseli s 10%-tnom sumpornom kiselinom, organsku fazu se temeljito ispere s otopinom natrijevog karbonata. Organsku fazu se osuši s natrijevim sulfatom, profiltrira i zatim koncentrira. Izolirano je 12,0 g (52%) proizvoda odgovarajuće čistoće.
b) 3,3-dimetil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid je proizveden postupkom poznatim iz literature (K. Auer, E. Hungerbüher, R.W. Lang Chimia 1990, 44, 120).
Analogno su proizvedeni:
3,3-dietil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid (talište: 174°С),
3,3-dimetil-6-nitro-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid (talište: 187°) i
3,3-dimetil-4-klor-2,3-dihidro-1,2-benzizotiazol-1,1-dioksid.
c) 2-(2-klorketil)-3,3-dimetil-2,3-dihidro-l,2-benzoizo-tiazol-1,1-dioksid
2,1 g (32 mM) 88% KOH praha i 250 mg benziltrietil-amonijevog klorida doda se k 2,5 g (12,7 mM) 3,3-dimetil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksida u 50 ml 1,2-dikloretana, i smjesu se refluktira 1 h. Kad se ohladi, smjesu se podijeli između ledene vode i metilen klorida i blago se zakiseli sa solnom kiselinom. Organsku fazu se odvoji. Zatim se organsku fazu osuši s natrijevim sulfatom i koncentrira. Izolirano je 3,2 g (97%) proizvoda kao ulja zadovoljavajuće čistoće.
Analognim postupkom mogu se proizvesti:
2-(2-kloretil)-3,3-dimetil-6-nitro-2,3-dihidro-12-benzoizotiazol-1,1-dioksid,
2-(2-kloretil)-3,3-dietil-2,3-dihidro-1,2-benzo-izotiazol-1,1-dioksid i
2-(2-kloretil)-4-kloro-3,3-dimetil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid.
d) (+)-(1S,5R,6S)-ekso-6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptan
(+)-enantiomer je izoliran metodom koja je opisana u Heterocycles 40 (1), 326 (1995).
e) (+)-(1S,5R,6S)-ekso-6-(4-klor)etil]-6-(4-klorfenil)-3-azabiciklo[3.2.0]heptan
7,3 g (50 mM) 1-brom-2-kloretana i 3,5 g (25 mM) finog prašakstog kalijevog karbonata doda se k 10,0 g (48,2 mM) (+)-(lS,5R,6S)-ekso-6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptana u 200 ml tetrahidrofurana i smjesu se refluktira 15 h. Zatim se smjesu koncentrira na rotacijskom isparivaču i ostatak se preuzme u 200 ml metil terc-butil etera. Organsku fazu se ispere s vodom pri pH 10 i zatim se vodenu fazu ponovno ekstrahira s metil terc-butil eterom. Sjedinjene organske faze se osuše s natrijevim sulfatom i zatim se koncentriraju. Sirov proizvod se očisti vakuumskom kromatografijom (silika gel, protočna faza etil acetat/n-heptan l/l). Izolirano je 6,7 g (52%) proizvoda kao ulja s [α]D = +91,7° (EtOH).
Analognim postupkom proizveden je (+)-(lS,5R,6S)-ekso-[3-(2-klor)etil]-6-(4-fluorfenil)-3-azabiciklo[3.2.0]-heptan.
В Prepravljanje krajnjih proizvoda
Primjer 1
(+)-(1S,5R,6S)-ekso-2-[2-[6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptan-3-il]etil]-3,3-dimetil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid x HCl
3,75 g (14,5 mM) 2-(2-kloretil)-3,3-dimetil-2,3-dihidro-l,2-benzoizotiazol-1,1-dioksida i 2,0 g (14,5 mM) finog praškastog kalijevog karbonata doda se k 3,0 g (14,5 mM) (+)-(lS,5R,6S)-ekso-6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptana u 60 ml ksilena i smjesu se refluktira 7 h. Zatim se koncentrira na rotacijskom isparivaču i ostatak se podijeli između vode i metilen klorida pri pH 10. Vodenu fazu se ekstrahira još jednom s metilen kloridom i zatim se sjedinjene organske faze koncentriraju. Sirov proizvod se očisti kromatografijom na stupcu (silika gel, protočna faza metilen klorid/metanol 98/2. Izolirano je 4,2 g (69%) proizvoda kao ulje koje se otopi u 200 ml etera i s eterskom HCl prevede se u hidroklorid (talište 230 do 232°C). [α]D = + 60,9° (EtOH)
Elementarna analiza С23Н27N2О2SСl х HCl
izračunato: С 59,10; H 6,04; N 5,99;
nađeno: С 59,3; H 6,3; N 5,7.
Primjer 2
(+)-(lS,5R,6S)-ekso-2-[2-[6-(4-klorfenil)-3-azabiciklo-[3.2.0]heptan-3-il)etil]-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid x НСl
360 mg (12,0 mM) 80% natrijevog hidrida doda se k 2,0 g (11,8 mM) 2,3-dihidro-l,2-benzoizotiazol-1,1-dioksida u 30 ml DMF-a i smjesu se miješa 2 h pri temperaturi kupelji od 90 do 100°C. Kad se ohladi doda se 3,2 g (11,8 mM) (+)-(lS,5R,6S)-ekso-[3-(2-klor)etil]-6-(4-klorfenil)-3-azabiciklo[3.2.0]heptana i smjesu se miješa 2 h pri temperaturi kupelji od 100°C. Kad se ohladi smjesu se podijeli između metil terc-butil etera i vode pri pH 10. Vodenu fazu se ekstrahira još jednom s metil terc-butil eterom. Organske faze se sjedine i koncentriraju. Sirov proizvod se očisti kromatografijom na stupcu (silika gel, protočna faza metilen klorid/metanol 98/2). Izolirano je 4,5 g (95%) proizvoda kao ulja ([α]D = + 69,9°; EtOH) koji se otopi u 200 ml etera i s eterskom HCl se prevede u hidroklorid (talište 240 do 242°C).
Elementarna analiza С21Н23N2О2SСl х HCl
izračunato: С 57,40; H 5,51; N 6,38; Cl 16,14;
nađeno: С 57,1; H 5,5; N 6,2; Cl 16,0.
Analogno primjerima 1 i 2 proizvedeni su slijedeći spojevi:
3. (+)-(1S,5R,6S)-ekso-2-[2-[6-(4-fluorfenil)-3-azabiciklo[3.2.0]heptan-3-il]etil]-3,3-dimetil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid, talište 113 do 115oC;
4. (+)-(1S,5R,6S)-ekso-2-[2-[6-(4-fluorfenil)-3-azabiciklo[3.2.0]heptan-3-il]etil]-3,3-dietil-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid x НСl x Н2О, tal. 77 do 79°C;
5. (+)-(1S,5R,6S)-ekso-2-[2-(6-(4-fluorfenil)-3-azabiciklo[3.2.0]heptan-3-il]etil]-2,3-dihidro-1,2-benzoizotiazol-1,1-dioksid x HCl, tal. 234 do 236°C, [α]D = + 67,1° (EtOH):
6. [3.2.0]heptan-3-il]-etil]-3,3-dimetil-4-kloro-2,3-dihidro-l,2-benzizotiazol-1,1-dioksid x HCl, tal. 225 do 227°C.
Claims (2)
1. N-supstituirani derivati 3-azabiciklo[3.2.0]-heptana formule I
[image]
naznačeni time, da
R1 je fluor ili klor,
R2 i R3 predstavljaju vodik ili C1-C3-alkil, i
R4 je klor, metil, nitro ili amino,
i njihove soli s fiziološki podnošljivim kiselinama.
2. Spoj formule I prema zahtjevu 1, naznačen time, da se upotrebljava za suzbijanje bolesti.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19836406A DE19836406A1 (de) | 1998-08-12 | 1998-08-12 | N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| PCT/EP1999/005164 WO2000009501A1 (de) | 1998-08-12 | 1999-07-20 | N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010180A2 true HRP20010180A2 (en) | 2002-04-30 |
Family
ID=7877217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010180A HRP20010180A2 (en) | 1998-08-12 | 2001-03-12 | N-substituted azabicycloheptane derivatives, production and use thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6300354B1 (hr) |
| EP (1) | EP1104419B1 (hr) |
| JP (1) | JP2002522539A (hr) |
| KR (1) | KR20010072408A (hr) |
| CN (1) | CN1312809A (hr) |
| AT (1) | ATE218138T1 (hr) |
| AU (1) | AU5285599A (hr) |
| BG (1) | BG105247A (hr) |
| BR (1) | BR9912885A (hr) |
| CA (1) | CA2339986A1 (hr) |
| CO (1) | CO5130024A1 (hr) |
| DE (2) | DE19836406A1 (hr) |
| DK (1) | DK1104419T3 (hr) |
| ES (1) | ES2178455T3 (hr) |
| HK (1) | HK1040399A1 (hr) |
| HR (1) | HRP20010180A2 (hr) |
| HU (1) | HUP0103358A3 (hr) |
| ID (1) | ID27656A (hr) |
| IL (1) | IL141009A0 (hr) |
| MY (1) | MY133140A (hr) |
| NO (1) | NO20010626D0 (hr) |
| NZ (1) | NZ510042A (hr) |
| PL (1) | PL345966A1 (hr) |
| PT (1) | PT1104419E (hr) |
| SK (1) | SK1382001A3 (hr) |
| TR (1) | TR200100475T2 (hr) |
| TW (1) | TW505644B (hr) |
| WO (1) | WO2000009501A1 (hr) |
| ZA (1) | ZA200101976B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547639A1 (en) * | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US20050143349A1 (en) * | 2003-12-17 | 2005-06-30 | Quatrx Pharmaceuticals Co. | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4219973A1 (de) | 1992-06-19 | 1993-12-23 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| DE4243287A1 (de) | 1992-06-19 | 1993-12-23 | Basf Ag | N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| DE4427648A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
| DE4341402A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| DE4427647A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
-
1998
- 1998-08-12 DE DE19836406A patent/DE19836406A1/de not_active Withdrawn
-
1999
- 1999-07-20 EP EP99938298A patent/EP1104419B1/de not_active Expired - Lifetime
- 1999-07-20 DE DE59901563T patent/DE59901563D1/de not_active Expired - Fee Related
- 1999-07-20 ID IDW20010352A patent/ID27656A/id unknown
- 1999-07-20 WO PCT/EP1999/005164 patent/WO2000009501A1/de not_active Application Discontinuation
- 1999-07-20 ES ES99938298T patent/ES2178455T3/es not_active Expired - Lifetime
- 1999-07-20 HU HU0103358A patent/HUP0103358A3/hu unknown
- 1999-07-20 PT PT99938298T patent/PT1104419E/pt unknown
- 1999-07-20 IL IL14100999A patent/IL141009A0/xx unknown
- 1999-07-20 DK DK99938298T patent/DK1104419T3/da active
- 1999-07-20 PL PL99345966A patent/PL345966A1/xx not_active IP Right Cessation
- 1999-07-20 CA CA002339986A patent/CA2339986A1/en not_active Abandoned
- 1999-07-20 BR BR9912885-3A patent/BR9912885A/pt not_active IP Right Cessation
- 1999-07-20 TR TR2001/00475T patent/TR200100475T2/xx unknown
- 1999-07-20 CN CN99809588A patent/CN1312809A/zh active Pending
- 1999-07-20 US US09/744,405 patent/US6300354B1/en not_active Expired - Fee Related
- 1999-07-20 NZ NZ510042A patent/NZ510042A/en unknown
- 1999-07-20 AU AU52855/99A patent/AU5285599A/en not_active Abandoned
- 1999-07-20 SK SK138-2001A patent/SK1382001A3/sk unknown
- 1999-07-20 KR KR1020017001781A patent/KR20010072408A/ko not_active Application Discontinuation
- 1999-07-20 AT AT99938298T patent/ATE218138T1/de not_active IP Right Cessation
- 1999-07-20 JP JP2000564953A patent/JP2002522539A/ja active Pending
- 1999-08-12 TW TW088114064A patent/TW505644B/zh active
- 1999-08-12 MY MYPI99003449A patent/MY133140A/en unknown
- 1999-08-12 CO CO99051370A patent/CO5130024A1/es unknown
-
2001
- 2001-02-06 NO NO20010626A patent/NO20010626D0/no not_active Application Discontinuation
- 2001-02-13 BG BG105247A patent/BG105247A/xx unknown
- 2001-03-09 ZA ZA200101976A patent/ZA200101976B/en unknown
- 2001-03-12 HR HR20010180A patent/HRP20010180A2/hr not_active Application Discontinuation
-
2002
- 2002-03-08 HK HK02101798.0A patent/HK1040399A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2178455T3 (es) | 2002-12-16 |
| NZ510042A (en) | 2003-08-29 |
| CO5130024A1 (es) | 2002-02-27 |
| DK1104419T3 (da) | 2002-09-23 |
| PT1104419E (pt) | 2002-09-30 |
| JP2002522539A (ja) | 2002-07-23 |
| CA2339986A1 (en) | 2000-02-24 |
| KR20010072408A (ko) | 2001-07-31 |
| MY133140A (en) | 2007-10-31 |
| TR200100475T2 (tr) | 2001-06-21 |
| PL345966A1 (en) | 2002-01-14 |
| BR9912885A (pt) | 2001-05-08 |
| BG105247A (en) | 2001-11-30 |
| CN1312809A (zh) | 2001-09-12 |
| HK1040399A1 (zh) | 2002-06-07 |
| DE19836406A1 (de) | 2000-02-17 |
| HUP0103358A2 (hu) | 2002-05-29 |
| IL141009A0 (en) | 2002-02-10 |
| EP1104419B1 (de) | 2002-05-29 |
| ZA200101976B (en) | 2002-03-11 |
| SK1382001A3 (en) | 2001-08-06 |
| ID27656A (id) | 2001-04-19 |
| NO20010626L (no) | 2001-02-06 |
| US6300354B1 (en) | 2001-10-09 |
| NO20010626D0 (no) | 2001-02-06 |
| ATE218138T1 (de) | 2002-06-15 |
| TW505644B (en) | 2002-10-11 |
| EP1104419A1 (de) | 2001-06-06 |
| WO2000009501A1 (de) | 2000-02-24 |
| DE59901563D1 (de) | 2002-07-04 |
| AU5285599A (en) | 2000-03-06 |
| HUP0103358A3 (en) | 2002-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150344444A1 (en) | Bet-protein-inhibiting dihydroxyquinoxalinones | |
| JP2020516666A (ja) | アポトーシス誘発剤 | |
| IL180757A (en) | Imidazo[4,5-d] pyrimidines, compositions comprising them and uses thereof for the preparation of medicaments | |
| JPH0517457A (ja) | ベンズイソチアゾールおよびベンズイソキサゾールピペラジン誘導体 | |
| MX2007011110A (es) | Formas de cristal de un derivado de imidazol. | |
| JP2002507611A (ja) | イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体 | |
| EP2020410B1 (fr) | Dérivés de pyrido[2,3-d] pyrimidine, leur préparation, leur application en thérapeutique | |
| KR20010013626A (ko) | 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및이의 제조 방법. | |
| US20240083907A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| CN102015642A (zh) | 新的3-氨基烷基-1,3-二氢-2h-吲哚-2-酮衍生物、其制备方法和其治疗用途 | |
| EP1567150B1 (fr) | Derives d indole-3-carboxamide, leur preparation et leur application en therapeutique | |
| US6028073A (en) | N-substituted 3-azabicyclo (3.2.0)heptane derivatives useful as neuroleptics | |
| FR2896246A1 (fr) | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. | |
| HRP940960A2 (en) | N-substituted azabicycloheptane derivatives, the preparation and use thereof | |
| HRP20010180A2 (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| HRP20010181A2 (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| US6458821B1 (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| CZ2001508A3 (cs) | N-Substituované azabicykloheptanové deriváty, způsob jejich přípravy a použití | |
| MX2007012242A (es) | Ciclohexan-1,4-diaminas sustituidas con piperacinilo. | |
| MXPA01001442A (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| JPS63277677A (ja) | エルゴリン誘導体およびその酸付加塩 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |